Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group, has announced that the FDA has licensed Pentacel, diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate vaccine.
Subscribe to our email newsletter
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use in infants and children six weeks through four years of age.
Pentacel vaccine is approved for administration as a four-dose series at two, four, six and 15-18 months of age. The first dose may be given as early as six weeks of age.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “Pentacel vaccine will help simplify the immunization schedule by reducing the number of injections infants and young children will receive in their first two years of life.”